179 related articles for article (PubMed ID: 29133135)
21. Copy number alteration features in pan-cancer homologous recombination deficiency prediction and biology.
Yao H; Li H; Wang J; Wu T; Ning W; Diao K; Wu C; Wang G; Tao Z; Zhao X; Chen J; Sun X; Liu XS
Commun Biol; 2023 May; 6(1):527. PubMed ID: 37193789
[TBL] [Abstract][Full Text] [Related]
22. Widespread BRCA1/2-independent homologous recombination defects are caused by alterations in RNA-binding proteins.
McGrail DJ; Li Y; Smith RS; Feng B; Dai H; Hu L; Dennehey B; Awasthi S; Mendillo ML; Sood AK; Mills GB; Lin SY; Yi SS; Sahni N
Cell Rep Med; 2023 Nov; 4(11):101255. PubMed ID: 37909041
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers for Homologous Recombination Deficiency in Cancer.
Wagener-Ryczek S; Merkelbach-Bruse S; Siemanowski J
J Pers Med; 2021 Jun; 11(7):. PubMed ID: 34203281
[TBL] [Abstract][Full Text] [Related]
24. Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer.
Vanderstichele A; Busschaert P; Olbrecht S; Lambrechts D; Vergote I
Eur J Cancer; 2017 Nov; 86():5-14. PubMed ID: 28950147
[TBL] [Abstract][Full Text] [Related]
25. Defective homologous recombination in human cancers.
Cerbinskaite A; Mukhopadhyay A; Plummer ER; Curtin NJ; Edmondson RJ
Cancer Treat Rev; 2012 Apr; 38(2):89-100. PubMed ID: 21715099
[TBL] [Abstract][Full Text] [Related]
26. Targeting homologous recombination repair defects in cancer.
Evers B; Helleday T; Jonkers J
Trends Pharmacol Sci; 2010 Aug; 31(8):372-80. PubMed ID: 20598756
[TBL] [Abstract][Full Text] [Related]
27. Functional variant analyses (FVAs) predict pathogenicity in the BRCA1 DNA double-strand break repair pathway.
Loke J; Pearlman A; Upadhyay K; Tesfa L; Shao Y; Ostrer H
Hum Mol Genet; 2015 Jun; 24(11):3030-7. PubMed ID: 25652403
[TBL] [Abstract][Full Text] [Related]
28. In vitro model for DNA double-strand break repair analysis in breast cancer reveals cell type-specific associations with age and prognosis.
Deniz M; Kaufmann J; Stahl A; Gundelach T; Janni W; Hoffmann I; Keimling M; Hampp S; Ihle M; Wiesmüller L
FASEB J; 2016 Nov; 30(11):3786-3799. PubMed ID: 27494941
[TBL] [Abstract][Full Text] [Related]
29. Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas.
Manié E; Popova T; Battistella A; Tarabeux J; Caux-Moncoutier V; Golmard L; Smith NK; Mueller CR; Mariani O; Sigal-Zafrani B; Dubois T; Vincent-Salomon A; Houdayer C; Stoppa-Lyonnet D; Stern MH
Int J Cancer; 2016 Feb; 138(4):891-900. PubMed ID: 26317927
[TBL] [Abstract][Full Text] [Related]
30. BRG1 promotes the repair of DNA double-strand breaks by facilitating the replacement of RPA with RAD51.
Qi W; Wang R; Chen H; Wang X; Xiao T; Boldogh I; Ba X; Han L; Zeng X
J Cell Sci; 2015 Jan; 128(2):317-30. PubMed ID: 25395584
[TBL] [Abstract][Full Text] [Related]
31. Mutational signatures reveal ternary relationships between homologous recombination repair, APOBEC, and mismatch repair in gynecological cancers.
Farmanbar A; Firouzi S; Kneller R; Khiabanian H
J Transl Med; 2022 Feb; 20(1):65. PubMed ID: 35109853
[TBL] [Abstract][Full Text] [Related]
32. Double-strand break repair and homologous recombination in Schizosaccharomyces pombe.
Raji H; Hartsuiker E
Yeast; 2006 Oct; 23(13):963-76. PubMed ID: 17072889
[TBL] [Abstract][Full Text] [Related]
33. Nonhomologous end-joining of ionizing radiation-induced DNA double-stranded breaks in human tumor cells deficient in BRCA1 or BRCA2.
Wang H; Zeng ZC; Bui TA; DiBiase SJ; Qin W; Xia F; Powell SN; Iliakis G
Cancer Res; 2001 Jan; 61(1):270-7. PubMed ID: 11196174
[TBL] [Abstract][Full Text] [Related]
34. Aberrations in DNA repair pathways in cancer and therapeutic significances.
Motegi A; Masutani M; Yoshioka KI; Bessho T
Semin Cancer Biol; 2019 Oct; 58():29-46. PubMed ID: 30922960
[TBL] [Abstract][Full Text] [Related]
35. Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?
Pawlyn C; Loehr A; Ashby C; Tytarenko R; Deshpande S; Sun J; Fedorchak K; Mughal T; Davies FE; Walker BA; Morgan GJ
Leukemia; 2018 Jul; 32(7):1561-1566. PubMed ID: 29467487
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic targeting and patient selection for cancers with homologous recombination defects.
Talens F; Jalving M; Gietema JA; Van Vugt MA
Expert Opin Drug Discov; 2017 Jun; 12(6):565-581. PubMed ID: 28425306
[TBL] [Abstract][Full Text] [Related]
37. [Cancer therapy by PARP inhibitors].
Seimiya H
Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
[TBL] [Abstract][Full Text] [Related]
38. Neuroendocrine Neoplasms Associated with Germline Pathogenic Variants in the Homologous Recombination Pathway.
Szybowska M; Mete O; Weber E; Silver J; Kim RH
Endocr Pathol; 2019 Sep; 30(3):237-245. PubMed ID: 30772928
[TBL] [Abstract][Full Text] [Related]
39. A quantitative model of the major pathways for radiation-induced DNA double-strand break repair.
Belov OV; Krasavin EA; Lyashko MS; Batmunkh M; Sweilam NH
J Theor Biol; 2015 Feb; 366():115-30. PubMed ID: 25261728
[TBL] [Abstract][Full Text] [Related]
40. Hyper-active non-homologous end joining selects for synthetic lethality resistant and pathological Fanconi anemia hematopoietic stem and progenitor cells.
Du W; Amarachintha S; Wilson AF; Pang Q
Sci Rep; 2016 Feb; 6():22167. PubMed ID: 26916217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
